Mechanism overviews · 29 papers
Peptidoteca
Readypep ↗
↳ Peptide Reference
GH axis

Ipamorelin

A selective growth-hormone-secretagogue pentapeptide used in GH-axis research.

Written by Peptidoteca Research Desk·Reviewed by Peptidoteca Research Desk·Last reviewed 2026-06-14·4 sources

§ In brief

Ipamorelin is a selective growth-hormone-secretagogue pentapeptide used in GH-axis research. It is supplied for laboratory research use only and is not approved for human or veterinary use. Its full amino-acid sequence is not characterised in this reference.

What is Ipamorelin?

A selective growth-hormone-secretagogue pentapeptide used in GH-axis research.

Ipamorelin is catalogued here as a reference compound for growth-hormone-axis research. The entry covers its chemical identity and the public databases that describe it; it is not a usage guide.

How is Ipamorelin studied?

Ipamorelin appears in the growth-hormone-axis literature, primarily in in-vitro and preclinical (animal) models. This page indexes 4 primary papers on Ipamorelin, each tagged with its study type below. Peptidoteca summarizes the proposed mechanism class and the primary sources rather than human outcomes; for the wider library, see the research library.

Is Ipamorelin approved for human use?

No. Ipamorelin is supplied for laboratory (in-vitro) research use only. It is not approved by the FDA or any comparable regulator for human or veterinary use, and nothing on this page constitutes medical advice, dosing guidance or a treatment recommendation.

What are the research limitations?

Most available evidence for Ipamorelin is preclinical — in-vitro and animal models — and findings in those models do not establish efficacy or safety in humans. Human clinical data is limited or absent, and Ipamorelin is not an approved drug. Treat the literature as mechanistic research, not clinical guidance.

§ Primary literature

  1. 1.Greenwood-Van Meerveld B (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology.Rodent studyIn a rodent model of postoperative ileus, the synthetic ghrelin-receptor agonist (mimetic) ipamorelin was reported to be associated with faster gastric emptying compared with control conditions in the study animals.
  2. 2.Venkova K (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics.Rodent studyIn a rodent model of postoperative ileus, the growth-hormone secretagogue and ghrelin-receptor agonist ipamorelin was reported to accelerate gastrointestinal transit in the animals studied.
  3. 3.Aagaard NK (2009). Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Hormone & IGF Research.Rodent studyIn a rodent model of prednisolone-induced catabolism, the synthetic growth-hormone-releasing peptide ipamorelin was examined alongside growth hormone for effects on hepatic nitrogen handling, with reported associations to urea-N synthesis capacity, urea-cycle enzyme expression, whole-body nitrogen balance, and organ nitrogen content in steroid-treated rats.
  4. 4.Sinha DK (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology.ReviewThis narrative review examines growth-hormone secretagogues, including ipamorelin (described as a synthetic pentapeptide and selective ghrelin/GHS-receptor agonist), alongside sermorelin, GHRP-2, GHRP-6, and ibutamoren, surveying reported effects on the GH axis and body-composition signaling and noting that the supporting evidence base remains limited.
Compound spec
Sequence not publicly characterised
ClassGH axis
CAS170851-70-4
Research vial5 / 10 mg

For in-vitro research only. Not medical, clinical or dosing advice.